These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 26603745)

  • 21. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
    Li C; Chen K; Cornelius V; Tomeny E; Wang Y; Yang X; Yuan X; Qin R; Yu D; Wu Z; Wang D; Chen T
    PLoS Med; 2021 Mar; 18(3):e1003515. PubMed ID: 33661907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicomponent intervention versus usual care for management of hypertension in rural Bangladesh, Pakistan and Sri Lanka: study protocol for a cluster randomized controlled trial.
    Jafar TH; Jehan I; de Silva HA; Naheed A; Gandhi M; Assam P; Finkelstein EA; Quigley HL; Bilger M; Khan AH; Clemens JD; Ebrahim S; Turner EL; ; Kasturiratne A
    Trials; 2017 Jun; 18(1):272. PubMed ID: 28606184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness of Drug Treatment for Chinese Patients With Stage I Hypertension According to the 2017 Hypertension Clinical Practice Guidelines.
    Zhou YF; Liu N; Wang P; Jeong Yang J; Song XY; Pan XF; Zhang X; He M; Li H; Gao YT; Xiang YB; Wu T; Yu D; Pan A
    Hypertension; 2020 Sep; 76(3):750-758. PubMed ID: 32713271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Remote blood pressure management for postpartum hypertension: a cost-effectiveness analysis.
    Mei JY; Hauspurg A; Corry-Saavedra K; Nguyen TA; Murphy A; Miller ES
    Am J Obstet Gynecol MFM; 2024 Sep; 6(9):101442. PubMed ID: 39074606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
    Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
    N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness of an adherence-improving programme in hypertensive patients.
    Brunenberg DE; Wetzels GE; Nelemans PJ; Dirksen CD; Severens JL; Stoffers HE; Schouten JS; Prins MH; de Leeuw PW; Joore MA
    Pharmacoeconomics; 2007; 25(3):239-51. PubMed ID: 17335309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of Intensive vs Standard Blood Pressure Control Among Older Patients With Hypertension.
    Liao CT; Toh HS; Sun L; Yang CT; Hu A; Wei D; Melgarejo J; Zhang ZY
    JAMA Netw Open; 2023 Feb; 6(2):e230708. PubMed ID: 36848091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension.
    Dorenkamp M; Bonaventura K; Leber AW; Boldt J; Sohns C; Boldt LH; Haverkamp W; Frei U; Roser M
    Eur Heart J; 2013 Feb; 34(6):451-61. PubMed ID: 23091202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.
    UK Prospective Diabetes Study Group
    BMJ; 1998 Sep; 317(7160):720-6. PubMed ID: 9732339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
    Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
    Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness of Antihypertensive Therapy in Patients Older Than 80 Years: Cohort Study and Markov Model.
    Hazra NC; Rudisill C; Jackson SH; Gulliford MC
    Value Health; 2019 Dec; 22(12):1362-1369. PubMed ID: 31806192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study.
    Lovibond K; Jowett S; Barton P; Caulfield M; Heneghan C; Hobbs FD; Hodgkinson J; Mant J; Martin U; Williams B; Wonderling D; McManus RJ
    Lancet; 2011 Oct; 378(9798):1219-30. PubMed ID: 21868086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
    Jönsson B; Carides GW; Burke TA; Dasbach EJ; Lindholm LH; Dahlöf B;
    J Hypertens; 2005 Jul; 23(7):1425-31. PubMed ID: 15942467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential health impact and cost-effectiveness of drug therapy for prehypertension.
    Chen T; Yu D; Cornelius V; Qin R; Cai Y; Jiang Z; Zhao Z
    Int J Cardiol; 2017 Aug; 240():403-408. PubMed ID: 28501349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control.
    Bress AP; Bellows BK; King JB; Hess R; Beddhu S; Zhang Z; Berlowitz DR; Conroy MB; Fine L; Oparil S; Morisky DE; Kazis LE; Ruiz-Negrón N; Powell J; Tamariz L; Whittle J; Wright JT; Supiano MA; Cheung AK; Weintraub WS; Moran AE;
    N Engl J Med; 2017 Aug; 377(8):745-755. PubMed ID: 28834469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Utility of an Objective Biochemical Measure to Improve Adherence to Antihypertensive Treatment.
    van Schoonhoven AV; van Asselt ADI; Tomaszewski M; Patel P; Khunti K; Gupta P; Postma MJ
    Hypertension; 2018 Nov; 72(5):1117-1124. PubMed ID: 30354817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
    Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
    Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK.
    Gladwell D; Henry T; Cook M; Akehurst R
    Appl Health Econ Health Policy; 2014 Dec; 12(6):611-22. PubMed ID: 25086585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M; Bienfait-Beuzon C; Jackson J
    J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of a brief education, self-management and upper limb exercise training in people with rheumatoid arthritis (EXTRA) programme: a trial-based analysis.
    Manning VL; Kaambwa B; Ratcliffe J; Scott DL; Choy E; Hurley MV; Bearne LM
    Rheumatology (Oxford); 2015 Feb; 54(2):302-9. PubMed ID: 25173349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.